Duchenne muscular dystrophy is associated with variable degrees of selective cognitive defect with lower scores for verbal intelligence and reading abilities. A number of findings have shown that rearrangements located in the second part of the gene seem to be preferentially associated with cognitive impairment. Several dystrophin transcripts are expressed in the brain. The more distal of them, Dp71, is predominant. We have carried out a mutational analysis of Dp 71 transcript in 12 DMD patients severely, mildly or not retarded, all without detectable deletion or duplication. We have detected five point mutations causing Dp 71 premature translation termination. All were found among the more severely mentally retarded patients of this group (VIQ < 50 and/or no reading acquisition).
Introduction
Duchenne muscular dystrophy (DMD) is a progressive X-linked muscle degenerative disorder, caused in most cases by large out-of-frame deletions or duplications in the dystrophin gene. 1 The remaining patients have more subtle mutations such as small insertions/deletions or nucleotide substitutions. 2 In both cases, mutations cause premature translation termination leading to an absence of dystrophin, a 427 kDa protein that is localised in the plasma membrane of muscle cells. Apart from the muscles, the brain is the major site of dystrophin expression. Two 427 kDa dystrophins, one active in neuronal cells of the cerebral cortex and the other expressed in cerebellar Purkinje neurons, originate from two distinct proximal promoters located in the vicinity of the muscle promoter. 3, 4 Two smaller alternative C-terminal products expressed in the brain, Dp140 and Dp71, have also been described. Dp140 is initiated upstream from exon 45 5 and Dp 71, between exons 62 and 63. 6, 7 These four DMD transcripts expressed in the brain retain the cysteine-rich and carboxyterminal domains of dystrophin which bind to a complex of sarcolemmal proteins known as the dystrophin associated proteins (DAPs). 8 In most patients, the muscle disease is associated with variable degrees of cognitive impairment, corresponding to significantly lower scores for verbal skills and delay in reading learning. 9 Several investigations have shown that rearrangements located in the second part of the gene tend to be more commonly associated with cognitive impairment than mutations located in the proximal part. [10] [11] [12] Recently
Bardoni et al 13 found a statistically significant correlation between the absence of Dp140 promoter and the presence of mental retardation in patients suffering from Becker muscular dystrophy (BMD), the allelic milder form of DMD. Moreover, many point mutations have been described in mentally retarded patients in the distal part of the gene corresponding to the Dp71 coding region. 14, 15 In a recent investigation, we found two promoter deleted Dp140 transcripts and two altered Dp71 transcripts (total absence of Dp71 transcript for one patient and a nonsense mutation for the other) respectively in four patients with severe cerebral dysfunction. 16 Both patients with Dp140 deletion had a QIV < 70 and bad or no reading acquisition, whereas both patients with altered Dp 71 transcripts were psychologically untestable because of severe mental deficiency. Taken together, these findings suggest that: (i) the cognitive impairment in some DMD patients may be related to dysfunction of certain brain DMD isoforms, and (ii) the degree of mental retardation might be related to the location of the mutation in the gene. It seems that the degree of cognitive impairment is more severe when the mutation is more distal.
To support this last hypothesis, we screened for point mutations in the Dp71 coding sequence in a group of 12 DMD patients without detectable deletion or duplication in the whole dystrophin cDNA sequence. Seven of the 12 patients were included in our previous study 16 
Materials and methods

Patients
After informed consent, all 12 patients were diagnosed on clinical features, progression of the disease, family history, markedly raised serum creatine kinase level and, when performed, absence of dystrophin on muscle biopsy. When patients could be tested, evaluation of cognitive abilities included verbal (VIQ) and visuospatial (PIQ) intelligence assessment (WISC-R scale) and/or reading skills assessment (Alouette test), as previously described. 16 Deletion and duplications screening had been performed both by multiplex PCR assays and Southern blotting covering the whole cDNA dystrophin sequence.
16
Dp 71 transcript analysis Dp71 transcript analysis was performed on total RNA isolated from lymphoblastoid cells. In brief, 5 µg of total RNA were reverse transcribed into cDNA using 100 pmol of random hexamers and 200 U of Superscript reverse transcriptase (Life Technologies, Inchinnan, UK) in 200 µl of buffer containing 1 mM of each dNTP and 20 U of RNAsin (Promega, Madison, WI, USA). An exogenous sample of reference RNA (50 ng of total rat liver RNA) was added as a source of internal standard for semi-quantitative Dp71 analysis.
The Dp71 transcript was analysed qualitatively by PCR amplification on 20 µl of the cDNA sample, as previously described. 16 PCR-amplified Dp71 cDNA was electrophoresed through 2% agarose gel and showed two bands of 2.1 kb and 1.8 kb, respectively. The latter band results from alternative splicing of exons 71 to 74. For each patient, the full-length top band was extracted from the gel and purified using the gel Extraction kit (Qiagen, Hilden, Germany). Direct sequencing was performed using the ABI PRISM dye terminator cycle sequencing system (Perkin Elmer, Warrington, UK) (primers used for sequencing are available on request). The product from the sequencing reaction was analysed using a 4.25% denaturing polyacrylamide gel with a fluorescent DNA sequencer (ABI PRISM 377 DNA Sequencer, Perkin Elmer). Data were analysed automatically. RT-PCR was performed twice when a mutation was found.
For semi-quantitative Dp71 analysis, PCR was performed on 10 µl of the cDNA sample with 50 pmol of a forward primer identical to a sequence of the specific exon of Dp 71 (as above), and 50 pmol of a reverse primer spanning nucleotides 9461-9482 in dystrophin cDNA, and on 50 pmol of two primers specific for rat liver L-type pyruvate kinase transcript (LPK1: AAGCAACGTAGCAGCATGGAA and LPK2: GGGTCAGTTGAGCCACAC TCG). The cycling conditions used were 94°C (1 min), 58°C (1 min), and 72°C (1 min) for 17 cycles. The final PCR products were Southern blotted and hybridised using an internal 5' labelled oligonucleotide probe (CTTGCAGCCATGAGGGAACA) for Dp71 transcript and 5' labelled primer LPK1 for rat liver pyruvate kinase transcript. 
Exon 66 analysis
Exon 66 and its intronic boundaries were amplified and sequenced with specific primers (Leiden Muscular Dystrophy pages, web information) from 200 ng of patient 69 genomic DNA. Table 2 summarizes the five sequence changes observed in the Dp71 coding sequence. All are translation termination mutations. Four of them are mutations of an arginine CGA codon corresponding to mutations at CpG sites, which are preferential sites for nonsense mutations 17 and have already been described 18, 19 (Leiden Muscular Dystrophy pages, web information). The fifth is a mutation in the splice donor site of intron 66. Analysis of Dp71 mRNA from patient 69 by RT-PCR showed an abnormal pattern of migration ( Figure 1 ). Two slightly smaller products than the predicted bands were detected. Sequence analysis of the top band revealed a 85 bp deletion corresponding to absence of exon 66 in the cDNA. This data was suggestive of an mRNA splicing defect. Exon 66 and its intronic boundaries were amplified from genomic DNA of patient 69 and controls. Direct sequencing showed a G to A substitution at position + 1 of the 5' donor site in intron 66. This mutation affects pre-mRNA maturation, leading to exon 66 skipping. The loss of exon 66 shifts the open reading frame, and thus introduces a termination codon at nucleotide position 9895 in exon 67. To the best of our knowledge this is a newly reported mutation. These five chain terminating mutations are predicted to affect full-length muscle and brain type 427 kDa dystrophins, either by truncation or by reduction of mRNA, or both, and should be considered causative of muscular disease. 2 In addition, Dp71 might also be affected by truncation, probably leading to disruption of its function. No mutation in Dp71 transcript was found in the five mildly or not retarded patients of this group (VIQ ≥ 70, with delayed or correct reading acquisition). The five patients with a mutation were among the seven severely mentally retarded patients (VIQ ≤ 50 and/or no reading acquisition or global mental deficiency). No mutation was found in Dp71 coding region in two patients (7 and 48) with severe cerebral dysfunction. Semi-quantitative analysis of Dp71 transcript by RT-PCR was performed to compare Dp71 transcript amount in these two patients with respect to patients with nonsense mutations and control ( Figure 2) . As usually observed, 20 a noticeable reduction in the level of Dp71 mRNA was observed in patients with a stop codon (patients 70 and 74). A similar reduction, indicative of an unstable mRNA and potentially in accordance with the psychometric phenotype, was observed for patient 7. It is possible that a mutation, located either in Dp71 regulatory sequences or in the polyadenylation region of the transcript and which could explain the low level of mRNA, has not been detected in this patient. For patient 48, we found no Finally, these results tend to confirm that mutations leading to premature translation termination in the Dp71 coding sequence are preferentially associated with severe mental retardation. Mutations in the distal part of the gene are likely to be associated with a loss of all isoforms expressed in the brain (including 427 kDa brain isoforms) and that could explain why these patients have a particularly severe cognitive phenotype. Therefore, distal mutations seem to be more deleterious for brain function than proximal mutations which lead only to a loss of cerebral and cerebellar dystrophins. Among 19 point mutations reported to date in the Dp71 region in DMD patients with a known cognitive phenotype, 16 were indeed found in mentally retarded patients. 14, 15, 18, 19, [21] [22] [23] [24] [25] [26] [27] [28] Only three mutations were found in patients of normal intelligence. 14, 27, 29 Two were located in exon 74 which is alternatively spliced in brain dystrophin isoforms, 30 and one in exon 79 which corresponds to the 3' untranslated region. Although some of the mutations described here have already been reported, their associated cognitive phenotype has not been described. This study in fact adds five point mutations in exons 62-79 associated with mental retardation.
Results and discussion
Why the loss or alteration of Dp71 protein should be deleterious for cognitive function is unknown. Transgenic mice experiments have shown that Dp71 cannot replace the function of full-length dystrophin and correct the muscle defect, although it does restore the DAP complex. 31 These results suggest that although Dp71 and dystrophin may interact with the same proteins they have distinct functions.
Greenberg et al 32 also demonstrated that mutant Dp71 deficient mice have a reduced level of DAP and conclude that Dp71 plays a role in the function or organisation of the DAP complex in the brain. It has been demonstrated that dystroglycan (a member of the DAP complex) and Dp 71 mRNAs, are co-located in some regions of the brain involved in certain cognitive processes. 33, 34 The early and gradually increased levels of Dp71 in the normal embryonic forebrain persisting to adulthood suggest its fundamental role during the development of the nervous system, 35 indicating that lack of Dp71 could impair cognitive function.
In conclusion, this study is consistent with previous findings concerning the association between cognitive disabilities and the presence of mutation in the specific Dp71 region in DMD patients. The systematic screening of point mutations in the gene is hindered by the size and complexity of the dystrophin gene. However, direct detection of the mutation in probands provides the basis of accurate genetic counselling of DMD families. This study indeed demonstrates that severe cognitive impairment is good clinical evidence to suggest searching for point mutations in the Dp71 region in DMD patients with no detectable deletion or duplication.
